Diagnosis and treatment of ECL cell tumors.
The diagnosis of ECL-omas is easy to perform. In patients with Zollinger-Ellison syndrome (ZES), ECL-omas are almost always observed in the setting of multiple endocrine neoplasia type I. In patients without ZES, the first step is to discard non-gastrin-related sporadic ECL-omas whose prognosis is poor. By contrast, prognosis of ECL-omas in patients with ZES or chronic atrophic gastritis is good. Metastases are rare, and tumor-related deaths are exceptional. In both conditions, ECL-omas measuring less than 1 cm should be treated by endoscopic polypectomy and survey. Treatment modalities (surgery, endoscopic polypectomy) for larger tumors are still discussed. The impact of endoscopic ultrasonography on the therapeutic decision has not yet been evaluated. Considering the good prognosis of these tumors, aggressive surgery could be limited to selected patients. Multicentric studies should be undertaken to determine the best treatment modalities.
Cadiot
G
G
Service d'Hépato-Gastroentérologie, CHU Bichat-Claude Bernard, Paris, France.
Cattan
D
D
Mignon
M
M
D002276:Carcinoid Tumor / Q000150:complications / Q000175:diagnosis* / Q000628:therapy*; D004724:Endoscopy; D019861:Enterochromaffin-like Cells / Q000473:pathology*; D005757:Gastritis, Atrophic / Q000150:complications / Q000473:pathology; D006801:Humans; D009853:Omeprazole / Q000627:therapeutic use; D013274:Stomach Neoplasms / Q000150:complications / Q000175:diagnosis* / Q000628:therapy*; D015043:Zollinger-Ellison Syndrome / Q000150:complications
D009853:Omeprazole